Go Pro
NYSE:BIO.B

Bio-Rad Laboratories (BIO.B) Stock Price, News & Analysis

Bio-Rad Laboratories logo
$365.08 0.00 (0.00%)
As of 09/21/2026

About Bio-Rad Laboratories Stock (NYSE:BIO.B)

Advanced

Key Stats

Today's Range
$365.08
$365.08
50-Day Range
$309.37
$387.39
52-Week Range
$244.54
$365.08
Volume
5 shs
Average Volume
24 shs
Market Capitalization
$9.76 billion
P/E Ratio
44.25
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bio-Rad Laboratories, Inc. (NYSE: BIO.B) develops, manufactures and supplies products and services used in life science research and clinical diagnostics. The company serves academic, pharmaceutical, biotechnology, industrial and healthcare customers, helping them analyze biological samples, conduct research and support diagnostic testing.

Its Life Science segment offers laboratory instruments, reagents, consumables and software for applications including polymerase chain reaction (PCR), digital PCR, droplet-based analysis, electrophoresis, chromatography, protein research, cell biology and gene expression. Bio-Rad also provides products used in food and beverage testing and other quality-control applications.

Through its Clinical Diagnostics segment, Bio-Rad supplies systems, reagents, controls and software for areas such as diabetes monitoring, infectious-disease testing, blood typing and immunohematology, quality control and autoimmune diagnostics. The company markets its products internationally through direct sales, distributors and service organizations.

Founded in 1952 by David and Alice Schwartz, Bio-Rad is headquartered in Hercules, California. Norman D. Schwartz has served as the company’s president and chief executive officer and is a member of the Schwartz family that has maintained a longstanding connection to the business.

AI Generated. May Contain Errors.

Receive BIO.B Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIO.B Stock News Headlines

Elon Musk’s Hushed FCC Filing. Sept 25th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.tc pixel
Bio-Rad Laboratories, Inc. Class B
See More Headlines

BIO.B Stock Analysis - Frequently Asked Questions

Bio-Rad Laboratories' stock was trading at $310.70 on January 1st, 2026. Since then, BIO.B stock has increased by 17.5% and is now trading at $365.08.

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) released its quarterly earnings results on Thursday, April, 30th. The company reported $1.89 EPS for the quarter. Bio-Rad Laboratories had a net margin of 8.59% and a trailing twelve-month return on equity of 3.54%.

The following companies are subsidiaries of Bio-Rad Laboratories: Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, QuantaLife, DiaMed Holding AG, Blackhawk Biosystems, and more.

Shares of BIO.B stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
4/30/2026
Today
9/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:BIO.B
CIK
12208
Employees
7,450
Year Founded
1952

Profitability

EPS (Trailing Twelve Months)
$8.25
Trailing P/E Ratio
44.25
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$759.90 million
Net Margins
8.59%
Pretax Margin
13.53%
Return on Equity
3.54%
Return on Assets
2.48%

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
3.14
Quick Ratio
2.33

Sales & Book Value

Annual Sales
$2.58 billion
Price / Sales
3.78
Cash Flow
$10.02 per share
Price / Cash Flow
36.43
Book Value
$276.16 per share
Price / Book
1.32

Miscellaneous

Outstanding Shares
26,740,000
Free Float
19,150,000
Market Cap
$9.76 billion
Optionable
Not Optionable
Beta
0.94

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NYSE:BIO.B) was last updated on 9/22/2026 by MarketBeat.com Staff.
From Our Partners